Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Avanos Medical Inc (NYSE:AVNS) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 3,292 shares of the company’s stock, valued at approximately $226,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Bollard Group LLC purchased a new position in shares of Avanos Medical in the third quarter worth approximately $100,000. Whittier Trust Co. purchased a new position in shares of Avanos Medical in the third quarter worth approximately $110,000. Public Employees Retirement System of Ohio purchased a new position in Avanos Medical during the second quarter valued at approximately $136,000. CENTRAL TRUST Co purchased a new position in Avanos Medical during the third quarter valued at approximately $167,000. Finally, Bank of Montreal Can purchased a new position in Avanos Medical during the third quarter valued at approximately $197,000. 88.96% of the stock is currently owned by institutional investors and hedge funds.

Shares of AVNS opened at $46.10 on Friday. Avanos Medical Inc has a 52 week low of $42.80 and a 52 week high of $72.96. The company has a market cap of $2.18 billion, a P/E ratio of 19.62 and a beta of 1.80. The company has a current ratio of 2.78, a quick ratio of 2.32 and a debt-to-equity ratio of 0.19.

Avanos Medical (NYSE:AVNS) last announced its quarterly earnings data on Tuesday, November 6th. The company reported $0.37 EPS for the quarter, beating the Zacks’ consensus estimate of $0.28 by $0.09. Avanos Medical had a net margin of 14.26% and a return on equity of 6.59%. The firm had revenue of $165.10 million for the quarter, compared to the consensus estimate of $166.57 million. Avanos Medical’s revenue was up 9.7% compared to the same quarter last year. On average, equities research analysts predict that Avanos Medical Inc will post 1.83 EPS for the current year.

A number of research analysts recently commented on AVNS shares. Raymond James raised shares of Avanos Medical from a “market perform” rating to an “outperform” rating in a research report on Tuesday, August 21st. Zacks Investment Research downgraded shares of Avanos Medical from a “buy” rating to a “hold” rating in a research report on Friday, August 10th. Morgan Stanley boosted their price objective on shares of Avanos Medical from $60.00 to $62.00 and gave the company an “underweight” rating in a research report on Thursday, October 11th. Barclays started coverage on shares of Avanos Medical in a research report on Monday, October 15th. They set an “equal weight” rating and a $69.00 price objective on the stock. Finally, TheStreet downgraded shares of Avanos Medical from a “b-” rating to a “c” rating in a research report on Wednesday, November 7th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company. Avanos Medical presently has a consensus rating of “Hold” and an average target price of $69.25.

In other Avanos Medical news, CEO Joseph Fralin Woody bought 3,500 shares of Avanos Medical stock in a transaction on Wednesday, November 28th. The stock was purchased at an average cost of $43.35 per share, for a total transaction of $151,725.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP John W. Wesley bought 1,000 shares of Avanos Medical stock in a transaction on Monday, November 19th. The stock was acquired at an average price of $47.48 per share, with a total value of $47,480.00. The disclosure for this purchase can be found here. Insiders have purchased 6,500 shares of company stock worth $286,685 over the last ninety days. 1.44% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION WARNING: This piece of content was reported by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.dailypolitical.com/2018/12/08/zurcher-kantonalbank-zurich-cantonalbank-takes-position-in-avanos-medical-inc-avns.html.

About Avanos Medical

Avanos Medical, Inc operates as a medical technology company that focuses on eliminating pain, speeding recovery, and preventing infection for healthcare providers and patients worldwide. Its Medical Devices segment provides a portfolio of products that focuses on respiratory and digestive health, along with surgical and interventional pain management.

Read More: Conference Calls

Want to see what other hedge funds are holding AVNS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Avanos Medical Inc (NYSE:AVNS).

Institutional Ownership by Quarter for Avanos Medical (NYSE:AVNS)

Receive News & Ratings for Avanos Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avanos Medical and related companies with MarketBeat.com's FREE daily email newsletter.